KCM
CGEM icon

Kennedy Capital Management’s Cullinan Oncology CGEM Stock Holding History

Kennedy Capital Management’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$965K Buy
53,010
+1,519
+3% +$22.6K 0.02% 512
2026
Q1 		$732K Buy
51,491
+4,225
+9% +$54.3K 0.02% 503
2025
Q4 		$489K Buy
47,266
+1,255
+3% +$11.3K 0.01% 512
2025
Q3 		$273K Buy
46,011
+33,837
+278% +$248K 0.01% 545
2025
Q2 		$91.7K Buy
12,174
+531
+5% +$4.27K ﹤0.01% 580
2025
Q1 		$88.1K Sell
11,643
-99,406
-90% -$954K ﹤0.01% 641
2024
Q4 		$1.35M Buy
+111,049
New +$1.6M 0.03% 564
2024
Q2 		– Sell
-84,234
Closed -$1.44M – 707
2024
Q1 		$1.44M Sell
84,234
-75,778
-47% -$1.17M 0.03% 579
2023
Q4 		$1.63M Sell
160,012
-329,434
-67% -$2.92M 0.04% 528
2023
Q3 		$4.43M Sell
489,446
-52,476
-10% -$547K 0.11% 310
2023
Q2 		$5.83M Sell
541,922
-43,020
-7% -$457K 0.14% 265
2023
Q1 		$5.98M Sell
584,942
-28,647
-5% -$316K 0.18% 217
2022
Q4 		$6.47M Sell
613,589
-25,321
-4% -$308K 0.18% 194
2022
Q3 		$8.19M Buy
638,910
+604,563
+1,760% +$8.15M 0.24% 134
2022
Q2 		$440K Buy
+34,347
New +$389K 0.01% 552

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Kennedy Capital Management's CGEM Position: Q2 2026 in Review

Kennedy Capital Management increased its Cullinan Oncology (CGEM) stake by 3% in Q2 2026, buying an estimated $22.6K and bringing the position to 53,010 shares worth $965K. The position accounts for 0.02% of the portfolio, ranked #512.

Kennedy Capital Management first reported a position in CGEM in Q2 2022 and has held it in 15 quarters since. The position peaked at $8.19M in Q3 2022. 184 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • Kennedy Capital Management held 53,010 shares of Cullinan Oncology worth $965K as of Q2 2026.
  • Kennedy Capital Management bought 1,519 Cullinan Oncology shares in Q2 2026, an estimated $22.6K.
  • Cullinan Oncology made up 0.02% of Kennedy Capital Management's portfolio in Q2 2026, its #512 holding.
  • Kennedy Capital Management first reported a position in Cullinan Oncology in Q2 2022 and has held it in 15 quarters since.
  • Kennedy Capital Management's Cullinan Oncology position peaked at $8.19M in Q3 2022.
  • 184 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on Kennedy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.